Svetomir N Markovic MD PhD

Clinical Trials

• Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Start of enrollment: 2000 Sep 01

  Completed

  Phase 2

• Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma Start of enrollment: 2000 Oct 01

  Completed

  Not Applicable

• Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung Start of enrollment: 2000 Oct 01

  Completed

  Phase 2

• Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Start of enrollment: 2002 May 01

  Completed

  Phase 1

• PS-341 in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2001 Jul 01

  Completed

  Phase 2

• Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System Start of enrollment: 2004 Jan 01

  Terminated

  Phase 2

• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2005 Dec 01

  Completed

  Phase 2

• Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01

  Completed

  Phase 2

• Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2004 Oct 01

  Completed

  Phase 1, Phase 2

• Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma Start of enrollment: 2007 Mar 01

  Completed

  Phase 1

• Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery Start of enrollment: 2006 Apr 01

  Completed

  Early Phase 1

• Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma Start of enrollment: 2006 Jun 01

  Terminated

  Phase 2

• Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma Start of enrollment: 2005 Nov 25

  Completed

  Phase 1

• Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2008 Jan 01

  Withdrawn

  Phase 1

• ABT-510 in Treating Patients With Metastatic Melanoma Start of enrollment: 2004 Nov 01

  Completed

  Phase 2

• Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2008 Aug 01

  Completed

  Phase 2

• Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer Start of enrollment: 2008 Aug 28

  Completed

  Early Phase 1

• Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Start of enrollment: 2008 Apr 08

  Completed

  Phase 1

• Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Start of enrollment: 2012 Oct 01

  Completed

  Early Phase 1

• Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy Start of enrollment: 2014 Mar 01

  Completed

  Early Phase 1

• Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative) Start of enrollment: 2013 Oct 01
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12

  COMPLETED

  PHASE3

• Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Start of enrollment: 2014 Feb 24

  COMPLETED

  PHASE1

• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01

  Completed

  Phase 2

• Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18

  Completed

  Phase 2

• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Start of enrollment: 2018 Apr 11

  ACTIVE_NOT_RECRUITING

  PHASE2, PHASE3

• Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma Start of enrollment: 2021 Sep 16

  TERMINATED

  PHASE1

• Join now to see all